01
What changed in pharmaceuticals regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
Nate Hill, CEO of Strive Pharmacy, discussed the regulatory outlook for compounded peptides following the FDA's Pharmacy Compounding Advisory Committee (PCAC) hearing.
Read at pharmexec.com ↗03
The US Food and Drug Administration (FDA) is expediting reviews for estradiol transdermal patches to address a supply shortage.
Read at citeline.com ↗04
Biotech company uniQure is preparing to file a Biologics License Application (BLA) for its gene therapy targeting Huntington's disease.
Read at citeline.com ↗05
On September 3, 2026, the US Food and Drug Administration (FDA) announced the cancellation of several postmarketing clinical trials for COVID-19 vaccines.
Read at citeline.com ↗06
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the use, supply, and sale of the drug Tavneos to new patients as of September 1, 2026.
Read at citeline.com ↗07
Entrepreneur Mark Cuban testified before the Texas state House on September 2, 2026, proposing five policy changes to improve healthcare affordability.
Read at fiercehealthcare.com ↗08
The National Institute for Health and Care Excellence (NICE) in England has updated its quality-of-life (QoL) value measurement tool for the first time in 30 years.
Read at citeline.com ↗8 of 21 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in pharmaceuticals this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
Australian biotech company ENA Respiratory has secured $2.98 million in funding from the government-backed Biointelect Venturer program.
Read at startupdaily.net ↗10
Roche has agreed to pay $190 million upfront to acquire a UCN2 analog for obesity treatment.
Read at fiercebiotech.com ↗11
Nestlé has agreed to sell its mainstream vitamins, minerals, and supplements business to private equity firm Yellow Wood Partners for $1 billion.
Read at esmmagazine.com ↗12
Roche has entered into a licensing agreement with Simcere Zaiming to acquire global rights for a preclinical trispecific antibody designed to treat B-cell-mediated diseases.
Read at fiercebiotech.com ↗13
Eli Lilly has agreed to acquire Merida Biosciences for up to $2.88 billion in cash to expand its portfolio into autoimmune disease treatments.
Read at thestreet.com ↗14
Eli Lilly has entered into a definitive agreement to acquire Merida Biosciences for a total consideration of up to $2.875 billion.
Read at fiercebiotech.com ↗15
Eli Lilly and Company has announced the acquisition of Merida for $2.9 billion.
Read at biopharmadive.com ↗16
Eli Lilly & Co. has announced plans to acquire Merida Biosciences Inc. for up to $2.88 billion in cash.
Read at bloomberg.com ↗8 of 16 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in pharmaceuticals this week?
Notable product launches, releases and platform updates from the week.
17
Ionis Pharmaceuticals has received regulatory approval for a treatment targeting Alexander disease, a rare genetic disorder.
Read at fiercebiotech.com ↗18
The FDA has approved a new HIV combination medication developed by Gilead Sciences.
Read at pharmavoice.com ↗19
On September 4, 2026, Chinese regulatory authorities approved the world's first nine-month prophylactic antibody treatment for infant Respiratory Syncytial Virus (RSV).
Read at citeline.com ↗20
The U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals' drug zilganersen, branded as Zanvastro, for the treatment of Alexander disease in children and adults.
Read at medcitynews.com ↗21
Ionis Pharmaceuticals has received approval for Zanvastro, the first disease-modifying drug for Alexander disease.
Read at citeline.com ↗22
Gilead Sciences has launched a new HIV awareness campaign titled 'Up to Date' in the United States.
Read at pharmavoice.com ↗23
The American Association of Pharmaceutical Scientists (AAPS) will host the 2026 PharmSci 360 conference from October 25–28, 2026, in New Orleans, Louisiana.
Read at drugdiscoverytrends.com ↗24
GSK and other pharmaceutical companies are seeking to enter the mRNA influenza vaccine market following the recent regulatory approval of Moderna's mRNA flu shot.
Read at citeline.com ↗8 of 9 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in pharmaceuticals this week?
Earnings, guidance and other financial results reported this week.
25
Electra Therapeutics has filed for an initial public offering (IPO) in 2026.
Read at fiercebiotech.com ↗26
Global biotech startup funding in 2026 is projected to remain stable between $36 billion and $40 billion, consistent with recent years.
Read at crunchbase.com ↗27
Norwegian retailer NorgesGruppen reported a 14.9% increase in operating revenue to NOK 69.3 billion for the first half of 2026.
Read at esmmagazine.com ↗3 of 4 financial results events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What court rulings and legal actions hit pharmaceuticals this week?
Court rulings, filings and legal actions reported this week.
28
Reckitt Benckiser won a unanimous federal jury verdict in Illinois on August 31, 2026, clearing Mead Johnson of liability regarding its Enfamil preterm infant formula.
Read at thegrocer.co.uk ↗1 of 2 courts and legal events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What research was published in pharmaceuticals this week?
New research findings and studies published this week.
29
A study published by the American Heart Association suggests that long-term melatonin use for over a year is associated with a 90 percent higher risk of developing congestive heart failure over a five-year period.
Read at futurism.com ↗30
Tal Zaks, the former chief medical officer of Moderna, has seen his significant financial investment in cancer treatment research begin to yield results.
Read at businessinsider.com ↗31
Novartis and its partner Ionis Pharmaceuticals reported that their experimental drug targeting Lp(a) failed to reduce the risk of major cardiovascular events in a Phase 3 clinical trial.
Read at fiercebiotech.com ↗32
Researchers have identified a potential link between higher GLP-1 receptor activity and male-pattern baldness.
Read at inc.com ↗33
AbbVie announced positive phase 3 clinical trial results for its bispecific T-cell engager, etentamig, on September 3, 2026.
Read at fiercebiotech.com ↗34
Ultragenyx Pharmaceutical reported that its phase 3 clinical trial for an Angelman syndrome treatment failed to meet its primary endpoints.
Read at fiercebiotech.com ↗35
Teva Pharmaceutical announced positive phase 2 clinical trial results for its anti-interleukin-15 antibody in treating celiac disease.
Read at fiercebiotech.com ↗36
On Wednesday, September 2, 2026, several major medical organizations including the AAFP, AAP, ACOG, and IDSA released independent vaccine recommendations for the 2026-27 respiratory virus season.
Read at fiercehealthcare.com ↗8 of 32 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit pharmaceuticals this week?
Incidents, outages and safety events reported this week.
37
Pharmaceutical manufacturer American Regent has recalled three lots of Epinephrine Injection, USP 30 mg/30 mL, due to the presence of particulate matter including glass, nylon, and other materials.
Read at gizmodo.com ↗38
Novartis and Bristol Myers Squibb have halted clinical studies for their autoimmune CAR-T cell therapies due to safety concerns.
Read at pharmavoice.com ↗39
McKesson Corporation confirmed a cybersecurity incident discovered on August 25, 2026, involving unauthorized access to data within its Oncology & Multispecialty and Medical-Surgical business units.
Read at fiercehealthcare.com ↗40
The hacking group ShinyHunters claimed responsibility for a cyberattack on the U.S. pharmaceutical distributor McKesson, which occurred during the week of August 24, 2026.
Read at techcrunch.com ↗4 of 5 incidents and safety events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What partnerships were announced in pharmaceuticals this week?
Partnerships, integrations and joint projects announced this week.
41
Carelon Research, led by president Mark Cziraky, has signed a partnership agreement with Manifold to enable life sciences researchers to analyze Carelon's real-world data (RWD) alongside third-party datasets.
Read at pharmexec.com ↗42
Carelon Research and Manifold have entered into a partnership to provide Manifold's research teams with access to Carelon's real-world data (RWD) sets.
Read at pharmexec.com ↗2 of 6 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What people moved in and out of pharmaceuticals roles this week?
Executive appointments and departures reported this week.
43
Alex Baldock has officially assumed the role of chief executive at the UK health and beauty retailer Boots as of September 1, 2026.
Read at retail-systems.com ↗1 of 7 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What else happened in pharmaceuticals this week?
Developments from the week that fit none of the other sections.
44
The U.S. Bureau of Labor Statistics projects a 35% growth in data science occupations between 2025 and 2035, creating 95,400 new jobs.
Read at biospace.com ↗45
The commercial growth of CAR-T cell therapies is currently hindered by the difficulty of scaling patient-specific manufacturing processes into a unified, reliable system.
Read at biopharmadive.com ↗2 of 16 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.